科伦博泰生物-B(股票代码:06990)与和铂医药共同宣布,其联合研发的创新药物SKB575/HBM7575用于治疗特应性皮炎的新药临床试验申请,已正式获得中国国家药品监督管理局的批准。
此次IND申请的获批,标志着该联合疗法在特应性皮炎治疗领域的研发进程取得重要进展。双方将继续推进后续临床试验工作,为患者提供新的治疗选择。
科伦博泰生物-B(股票代码:06990)与和铂医药共同宣布,其联合研发的创新药物SKB575/HBM7575用于治疗特应性皮炎的新药临床试验申请,已正式获得中国国家药品监督管理局的批准。
此次IND申请的获批,标志着该联合疗法在特应性皮炎治疗领域的研发进程取得重要进展。双方将继续推进后续临床试验工作,为患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.